---
title: "Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291592393.md"
description: "Vor Bio (Nasdaq: VOR) announced that its Compensation Committee granted stock options for 71,200 shares and RSUs for 15,150 shares to seven newly hired employees on July 1, 2026. These grants serve as material inducements under Nasdaq Listing Rule 5635(c)(4). The options have a $18.39 exercise price and vest over four years, while RSUs also vest over four years, subject to continued employment."
datetime: "2026-07-02T13:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291592393.md)
  - [en](https://longbridge.com/en/news/291592393.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291592393.md)
---

# Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and an exercise price of $18.39 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

**About Vor Bio**

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

  
  

Media & Investor Contacts:Carl Mauchcmauch@vorbio.com

### Related Stocks

- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

- [Vor Bio grants inducement awards to new hires, including options for 71,200 shares at $18.39](https://longbridge.com/en/news/291592170.md)
- [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News](https://longbridge.com/en/news/288330248.md)
- [Q32 Bio Inc. (NASDAQ:QTTB) Sees Large Increase in Short Interest](https://longbridge.com/en/news/293861610.md)
- [Cardiovascular diseases biotech Braveheart Bio sets terms for $300 million IPO](https://longbridge.com/en/news/294370065.md)
- [Scorpio Gold pursues Nasdaq listing for American depositary shares](https://longbridge.com/en/news/293905134.md)